Femara and Encephalopathy - a phase IV clinical study of FDA data

Summary:

Encephalopathy is reported as a side effect among people who take Femara (letrozole), especially for people who are female, 50-59 old, have been taking the drug for < 1 month also take Zometa, and have Breast cancer metastatic.

The phase IV clinical study analyzes which people have Encephalopathy when taking Femara. It is created by eHealthMe based on reports of 19,093 people who have side effects when taking Femara from the FDA, and is updated regularly.

What is Femara?

Femara has active ingredients of letrozole. It is often used in breast cancer. eHealthMe is studying from 19,630 Femara users. Check the latest studies of Femara.

What is Encephalopathy?

Encephalopathy (functioning of the brain is affected by some agent or condition) is found to be associated with 1,465 drugs and 1,602 conditions by eHealthMe. Check the latest studies of Encephalopathy.

On Jul, 13, 2026

19,093 people reported to have side effects when taking Femara.
Among them, 32 people (0.17%) have Encephalopathy.

Among these 32 people:

How long have people been on Femara when they have Encephalopathy? *

What is the gender of people who have Encephalopathy when taking Femara? *

female: 93.75 %
male: 6.25 %

What is the age of people who have Encephalopathy when taking Femara? *

What are other drugs people take besides Femara? *

What are other side effects people have besides Encephalopathy? *

Pain: 15 people, 46.88%
Anaemia (lack of blood): 14 people, 43.75%
Stress And Anxiety: 14 people, 43.75%
Nausea And Vomiting: 13 people, 40.62%
Dehydration (dryness resulting from the removal of water): 13 people, 40.62%
Nausea (feeling of having an urge to vomit): 12 people, 37.50%
Injury: 12 people, 37.50%
Osteomyelitis (infection of bone): 12 people, 37.50%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 12 people, 37.50%
Periodontitis (inflammation of the tissue around the teeth): 12 people, 37.50%

What are the existing conditions these people have? *

Breast Cancer Metastatic: 8 people, 25.00%
Stroke (sudden death of a portion of the brain cells due to a lack of oxygen): 6 people, 18.75%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 6 people, 18.75%
Cerebral Haemorrhage (bleeding within the brain): 4 people, 12.50%
Neoplasm Malignant (cancer tumour): 3 people, 9.38%
Metastases To Bone (cancer spreads to bone): 3 people, 9.38%
Hypercalcaemia (elevated calcium (ca+) level in the blood): 2 people, 6.25%
Cancer Pain: 2 people, 6.25%
Ulcerative Colitis (inflammatory bowel disease (ibd). it causes swelling, ulcerations, and loss of function of the large intestine): 1 person, 3.12%
Type 2 Diabetes: 1 person, 3.12%

* Approximation only. Some reports may have incomplete information.

Do you take Femara and have Encephalopathy?

- Check whether Encephalopathy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Femara:

Femara (19,630 reports)

Encephalopathy treatments and more:

Encephalopathy (27,832 reports)

Browse all side effects of Femara:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Encephalopathy:

Encephalopathy (1,465 drugs)

Browse all the conditions that are associated with Encephalopathy:

Encephalopathy (1,602 conditions)

Related publications that referenced our studies

Kapoor A, Kumar V, Beniwal S, Dutta S, Goyal S, Kumar HS, "Posterior reversible encephalopathy syndrome in non-Hodgkin's lymphoma: Not necessarily reversible!", Clinical Cancer Investigation Journal, 2015 Mar .
Kapoor A, Kumar V, Beniwal S, Dutta S, Goyal S, Kumar HS, "Posterior reversible encephalopathy syndrome in non-Hodgkin's lymphoma: Not necessarily reversible!", Clinical Cancer Investigation Journal, 2015 Mar .

How the study uses the data?

The study uses data from the FDA. It is based on letrozole (the active ingredients of Femara) and Femara (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.